116 related articles for article (PubMed ID: 24642241)
1. A parallel study of careHPV and Hybrid Capture 2 human papillomavirus DNA testing for cervical cancer screening in rural China.
Lin CQ; Chen F; Liu B; Zhang YZ; Cui XL; Li AM; Zhang WH; Chen W; Chang I; Sivasubramaniam P; Zhu J; Qiao YL
J Virol Methods; 2014 Jun; 202():73-8. PubMed ID: 24642241
[TBL] [Abstract][Full Text] [Related]
2. The concordance of HPV DNA detection by Hybrid Capture 2 and careHPV on clinician- and self-collected specimens.
Chen W; Jeronimo J; Zhao FH; Qiao YL; Valdez M; Zhang X; Kang LN; Bansil P; Paul P; Bai P; Peck R; Li J; Chen F; Stoler MH; Castle PE
J Clin Virol; 2014 Dec; 61(4):553-7. PubMed ID: 25453572
[TBL] [Abstract][Full Text] [Related]
3. Optimal positive cutoff points for careHPV testing of clinician- and self-collected specimens in primary cervical cancer screening: an analysis from rural China.
Kang LN; Jeronimo J; Qiao YL; Zhao FH; Chen W; Valdez M; Zhang X; Bansil P; Paul P; Bai P; Peck R; Li J; Chen F; Stoler MH; Castle PE
J Clin Microbiol; 2014 Jun; 52(6):1954-61. PubMed ID: 24671789
[TBL] [Abstract][Full Text] [Related]
4. Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobas® HPV Test results from the ATHENA study.
Rao A; Sandri MT; Sideri M; Young S; Sharma A; Behrens C
J Clin Virol; 2013 Sep; 58(1):161-7. PubMed ID: 23895930
[TBL] [Abstract][Full Text] [Related]
5. Agreement between careHPV and hybrid capture 2 in detecting high-risk HPV in women in Tanzania.
Katanga J; Kjaer SK; Manongi R; Pembe AB; Iftner T; Waldstrom M; Mwaiselage J; Rasch V
Acta Obstet Gynecol Scand; 2021 Apr; 100(4):786-793. PubMed ID: 33497480
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a multiplex real time PCR assay for the detection of human papillomavirus infections on self-collected cervicovaginal lavage samples.
Jentschke M; Soergel P; Hillemanns P
J Virol Methods; 2013 Oct; 193(1):131-4. PubMed ID: 23707925
[TBL] [Abstract][Full Text] [Related]
7. Comparison of careHPV and hybrid capture 2 assays for detection of high-risk human Papillomavirus DNA in cervical samples from HIV-1-infected African women.
Ngou J; Magooa MP; Gilham C; Djigma F; Didelot MN; Kelly H; Yonli A; Sawadogo B; Lewis DA; Delany-Moretlwe S; Mayaud P; Segondy M;
J Clin Microbiol; 2013 Dec; 51(12):4240-2. PubMed ID: 24108613
[TBL] [Abstract][Full Text] [Related]
8. Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?
Fokom Domgue J; Schiffman M; Wentzensen NH; Gage JC; Castle PE; Raine-Bennett TR; Fetterman B; Lorey T; Poitras NE; Befano B; Xie Y; Miachon LS; Dean M
J Clin Microbiol; 2017 Aug; 55(8):2348-2355. PubMed ID: 28515214
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Anyplex II HPV28 assay with the Hybrid Capture 2 assay for the detection of HPV infection.
Kwon MJ; Roh KH; Park H; Woo HY
J Clin Virol; 2014 Apr; 59(4):246-9. PubMed ID: 24568964
[TBL] [Abstract][Full Text] [Related]
10. [Cost-effectiveness analysis on the once-in-a-lifetime cervical cancer screening program for women living in rural and urban areas of China].
Xu H; Zhao FH; Gao XH; Hu SY; Chen JF; Liu ZH; Xu XL; Gao LM; Liu QG; Ma L; Liu YJ; Qiao YL
Zhonghua Liu Xing Bing Xue Za Zhi; 2013 Apr; 34(4):399-403. PubMed ID: 23937850
[TBL] [Abstract][Full Text] [Related]
11. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
12. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China.
Qiao YL; Sellors JW; Eder PS; Bao YP; Lim JM; Zhao FH; Weigl B; Zhang WH; Peck RB; Li L; Chen F; Pan QJ; Lorincz AT
Lancet Oncol; 2008 Oct; 9(10):929-36. PubMed ID: 18805733
[TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening.
Poljak M; Ostrbenk A; Seme K; Ucakar V; Hillemanns P; Bokal EV; Jancar N; Klavs I
J Clin Microbiol; 2011 May; 49(5):1721-9. PubMed ID: 21430098
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China.
Zhao FH; Jeronimo J; Qiao YL; Schweizer J; Chen W; Valdez M; Lu P; Zhang X; Kang LN; Bansil P; Paul P; Mahoney C; Berard-Bergery M; Bai P; Peck R; Li J; Chen F; Stoler MH; Castle PE
Cancer Prev Res (Phila); 2013 Sep; 6(9):938-48. PubMed ID: 23878179
[TBL] [Abstract][Full Text] [Related]
15. An HPV 16, 18, and 45 genotyping test based on Hybrid Capture technology.
Thai H; Rangwala S; Gay T; Keating K; McLeod S; Nazarenko I; O'Neil D; Pfister D; Loeffert D
J Clin Virol; 2009 Jul; 45 Suppl 1():S93-7. PubMed ID: 19651375
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the Performance of Hybrid Capture 2 Test as a Primary Screening Test from Studies Conducted in Low and Middle-Income Country Settings- Special Focus India.
Anand KV; Pimple SA; Bhattacharjee A; Mishra GA; Shastri SS
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2709-2716. PubMed ID: 34452578
[TBL] [Abstract][Full Text] [Related]
17. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types.
Castle PE; Schiffman M; Burk RD; Wacholder S; Hildesheim A; Herrero R; Bratti MC; Sherman ME; Lorincz A
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1394-9. PubMed ID: 12433717
[TBL] [Abstract][Full Text] [Related]
18. [Study on the value assessment of various screening programs regarding cervical cancer screening strategy in the rural areas of China].
Li LY; Qiao ZQ; Zhang MF; Yang JP; Bao YP; An YT; Lei J; Xiong NH; Yu XH; Zhang X; Pan QJ; Qiao YL
Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Oct; 28(10):964-7. PubMed ID: 18399140
[TBL] [Abstract][Full Text] [Related]
19. Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention.
Surriabre P; Torrico A; Vargas T; Ugarte F; Rodriguez P; Fontaine V
BMC Infect Dis; 2019 Oct; 19(1):842. PubMed ID: 31615443
[TBL] [Abstract][Full Text] [Related]
20. The next-generation Hybrid Capture High-Risk HPV DNA assay on a fully automated platform.
Eder PS; Lou J; Huff J; Macioszek J
J Clin Virol; 2009 Jul; 45 Suppl 1():S85-92. PubMed ID: 19651374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
